DFDA

Durvalumab + Gemcitabine/Cisplatin

Treatment for Gallbladder And Biliary Tract Cancer

Typical Dosage: Durvalumab 1500mg IV every 3 weeks (with GemCis for 8 cycles, then monotherapy)

Effectiveness
60%
Safety Score
28%
Clinical Trials
5
Participants
10K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
28
DangerousModerateSafe
Treatment Details
Dosage Range
Durvalumab 1500mg IV every 3 weeks (with GemCis for 8 cycles, then monotherapy)
Time to Effect
1-3 months
Treatment Duration
Until progression or unacceptable toxicity (6-18+ months)
Evidence Quality
HIGH
Number Needed to Treat (NNT)
12(Treat 12 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$130,000
Monitoring:$20,000
Side Effect Mgmt:$15,000
Total Annual:$165,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$300,000/QALY
QALYs Gained
0.9
Outcome-Based Costs
Cost per Responder
$611,111
Cost per Remission
$5,500,000
Comparison vs Gemcitabine + Cisplatin
Cost Difference
+$120,000/year
More expensive
QALY Difference
+0.15 QALYs
Better outcomes
Dominance
No dominance
Durvalumab + Gemcitabine/Cisplatin Outcomes

for Gallbladder And Biliary Tract Cancer

Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+27%
Remission Rate
+3%
Common Side Effects
Myelosuppression
+55%
Fatigue
+60%
Nausea/Vomiting
+40%
Peripheral neuropathy
+30%
Immune-related adverse events
+10%

Sources:

nih.gov
nih.gov
onclive.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
5 active trials recruiting for Durvalumab + Gemcitabine/Cisplatin in Gallbladder And Biliary Tract Cancer

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

NCT07221253RECRUITINGPHASE3
View Study
1.1K participants
INTERVENTIONAL
Birmingham, United States +176 more
Started: Dec 4, 2025

Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer

NCT04308174ACTIVE NOT RECRUITINGPHASE2
View Study
45 participants
INTERVENTIONAL
Seoul, South Korea
Started: May 20, 2020

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575RECRUITINGPHASE3
View Study
286 participants
INTERVENTIONAL
Duarte, United States +184 more
Started: Jul 19, 2024

Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma

NCT07780838RECRUITINGPHASE2
View Study
29 participants
INTERVENTIONAL
Columbus, United States
Started: Nov 1, 2026

Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer

NCT07765433NOT YET RECRUITINGPHASE2, PHASE3
View Study
336 participants
INTERVENTIONAL
Started: Jan 11, 2027
Completed Clinical Trials
1 completed trial for Durvalumab + Gemcitabine/Cisplatin in Gallbladder And Biliary Tract Cancer

Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients

NCT03473574COMPLETEDPHASE2
View Study
128 participants
INTERVENTIONAL
Hanover, Germany
Started: May 2, 2018